Pulmonary Fibrosis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:

Description

The global pulmonary fibrosis treatment market is experiencing significant growth due to the rising prevalence of pulmonary fibrosis and advancements in therapeutic approaches. Pulmonary fibrosis is a condition where lung tissue becomes scarred, leading to decreased lung capacity for oxygen exchange.In 2024, the market is projected to reach USD 3.24 billion, with expectations to rise to USD 5.07 billion by 2031, reflecting a compound annual growth rate (CAGR) of 6.60%.While it remains an incurable disease, various treatments have been developed to manage the symptoms and slow the progression of the condition, extending patient survival and improving quality of life.

Pulmonary fibrosis is often linked to interstitial lung diseases, which involve inflammation and scarring of the lung's interstitium-the tissue surrounding the air sacs of the lungs. As the disease progresses, the scarring worsens, leading to severe breathing difficulties. The exact cause of pulmonary fibrosis is not always known, but risk factors include exposure to environmental pollutants, certain medications, and autoimmune diseases. The most common type, idiopathic pulmonary fibrosis (IPF), has no known cause, making treatment more challenging.

In recent years, extensive research has been conducted to understand the underlying mechanisms of pulmonary fibrosis and to develop effective treatments. Many academic institutions and pharmaceutical companies are focusing on innovative therapeutic pathways. These efforts have led to the development of drugs that can manage the condition, offering patients hope for a better quality of life.

The Analysis of pulmonary fibrosis treatment has evolved significantly with the introduction of new therapies. Historically, treatment options were limited, with patients relying on off-label use of immunosuppressive drugs such as corticosteroids. However, the approval of new drugs has revolutionized treatment, particularly in Western countries. These drugs have shown promise in slowing the progression of the disease, and their introduction has driven increased adoption rates.

Despite the advancements, there are still challenges in the global pulmonary fibrosis treatment market. One of the primary issues is the limited availability of treatment options, particularly in low and middle-income countries. In these regions, the diagnosis rate is often low, and patients are frequently diagnosed at advanced stages of the disease, which complicates treatment. Moreover, the high cost of drugs and limited access to newer therapies are significant barriers to effective treatment.

Another challenge in managing pulmonary fibrosis is the presence of comorbidities. Many patients with pulmonary fibrosis also suffer from other conditions, such as pulmonary hypertension, which can complicate treatment and worsen outcomes. The complexity of managing multiple conditions simultaneously requires a comprehensive approach to treatment, often involving combination therapies.

To address these challenges, drug manufacturers are focusing on developing a robust pipeline of new therapies. These companies are engaged in extensive research and development activities, aiming to bring new drugs to market that offer better efficacy and fewer side effects. The introduction of large molecule biologics is expected to play a crucial role in the future of pulmonary fibrosis treatment, with several potential therapies currently under evaluation.

One significant development in the field of pulmonary fibrosis treatment is the growing recognition of the need for precision medicine. Precision medicine involves tailoring treatment to the individual characteristics of each patient, including their genetic makeup and the specific molecular pathways involved in their disease. This approach has the potential to significantly improve treatment outcomes by providing more targeted and effective therapies.

For instance, ongoing research initiatives are exploring the genetic and molecular basis of pulmonary fibrosis, with the goal of developing therapies that target the underlying causes of the disease. These efforts are supported by substantial funding from governmental and philanthropic organizations, highlighting the importance of this research in the fight against pulmonary fibrosis.

In addition to drug development, there is a growing emphasis on improving diagnostic tools and increasing awareness of pulmonary fibrosis. Early diagnosis is critical for effective treatment, yet many patients are diagnosed only after the disease has significantly progressed. Improved diagnostic techniques, including advanced imaging and biomarker identification, are essential for identifying the disease at an earlier stage, allowing for timely intervention.

The role of regulatory agencies is also crucial in shaping the pulmonary fibrosis treatment market. Regulatory bodies, such as the U.S. FDA, have implemented programs to accelerate the development and approval of new therapies. The orphan drug designation, for example, provides incentives for the development of treatments for rare diseases, including pulmonary fibrosis. These incentives include marketing exclusivity, tax credits, and grants, which encourage pharmaceutical companies to invest in the development of new therapies.

Several companies have already benefited from these regulatory initiatives. For example, certain drugs have received breakthrough therapy designation, which expedites their development and review process. This designation is reserved for therapies that show substantial improvement over existing treatments for serious conditions. The introduction of these new drugs is expected to drive significant market growth, as they offer new hope to patients with pulmonary fibrosis.

The competitive Analysis of the pulmonary fibrosis treatment market is characterized by the presence of several leading pharmaceutical companies. These companies are actively involved in mergers and acquisitions, strategic collaborations, and research partnerships to strengthen their market position and expand their product portfolios. The focus on innovation and the development of new therapies is expected to intensify competition in the market, driving further advancements in treatment options.

In terms of regional markets, the United States is a leading market for pulmonary fibrosis treatment, driven by the high prevalence of the disease and the availability of advanced therapies. The U.S. market is also supported by a robust healthcare infrastructure and strong regulatory support for the development of new treatments. Additionally, the prevalence of smoking, a significant risk factor for pulmonary fibrosis, remains high in the U.S., contributing to the demand for treatment.

In Europe, Germany is a key market for pulmonary fibrosis treatment, with a high adoption rate of new therapies. The country's aging population, coupled with its strong medical device industry, drives demand for pulmonary fibrosis treatments. The German market also benefits from significant investments in research and development, which support the development of new therapies and diagnostic tools.

Japan is another prominent market, supported by its strong healthcare system and significant investment in research and development. The availability of a skilled workforce and advanced manufacturing capabilities also contribute to Japan's leading position in the pulmonary fibrosis treatment market.

The global market is segmented by therapy type, indication, and distribution channel. Monotherapy remains the most widely used treatment approach, driven by its effectiveness and lower risk of drug interactions. The idiopathic pulmonary fibrosis segment is the largest by indication, reflecting the high prevalence of this condition. Retail pharmacies are the primary distribution channel, offering easy access to prescription and over-the-counter medications.

Key Companies Profiled

F. Hoffman - La Roche Ltd.
Boehringer Ingelheim
International GmbH
Cipla Ltd (Cipla)
Gilead Sciences, Inc.
Bristol-Myers Squibb Company
FibroGen Inc.,
Galecto, Inc.

Key Segments Covered in Pulmonary Fibrosis Treatment Industry Research

By Therapy Type:

Monotherapy
- Pirfenidone Therapy
- Nintedanib Therapy
- Corticosteroids Therapy
Combination Therapy
- Pirfenidone & Corticosteroid
- Nintedanib & Corticosteroid
- Pirfenidone & Antitussive
- Others
Symptomatic Treatment

By Indication:

Idiopathic Pulmonary Fibrosis (IPF)
Familial PF
Others

By Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Mail Order Pharmacy

By Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

1. Executive Summary

1.1. Global Pulmonary Fibrosis Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2024
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Pulmonary Fibrosis Treatment Market Outlook, 2019 - 2031

3.1. Global Pulmonary Fibrosis Treatment Market Outlook, by Therapy Type, Value (US$ Bn), 2019 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Monotherapy
    - 3.1.1.1.1. Pirfenidone Therapy
    - 3.1.1.1.2. Nintedanib Therapy
    - 3.1.1.1.3. Corticosteroids Therapy
  - 3.1.1.2. Combination Therapy
    - 3.1.1.2.1. Pirfenidone & Corticosteroid
    - 3.1.1.2.2. Nintedanib & Corticosteroid
    - 3.1.1.2.3. Pirfenidone & Antitussive
    - 3.1.1.2.4. Others
  - 3.1.1.3. Symptomatic Treatment
3.2. Global Pulmonary Fibrosis Treatment Market Outlook, by Indication, Value (US$ Bn), 2019 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Idiopathic Pulmonary Fibrosis (IPF)
  - 3.2.1.2. Familial PF
  - 3.2.1.3. Others
3.3. Global Pulmonary Fibrosis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. Hospital Pharmacy
  - 3.3.1.2. Retail Pharmacy
  - 3.3.1.3. Mail Order Pharmacy
3.4. Global Pulmonary Fibrosis Treatment Market Outlook, by Region, Value (US$ Bn), 2019 - 2031
- 3.4.1. Key Highlights
  - 3.4.1.1. North America
  - 3.4.1.2. Europe
  - 3.4.1.3. Asia Pacific
  - 3.4.1.4. Latin America
  - 3.4.1.5. Middle East & Africa

4. North America Pulmonary Fibrosis Treatment Market Outlook, 2019 - 2031

4.1. North America Pulmonary Fibrosis Treatment Market Outlook, by Therapy Type, Value (US$ Bn), 2019 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Monotherapy
    - 4.1.1.1.1. Pirfenidone Therapy
    - 4.1.1.1.2. Nintedanib Therapy
    - 4.1.1.1.3. Corticosteroids Therapy
  - 4.1.1.2. Combination Therapy
    - 4.1.1.2.1. Pirfenidone & Corticosteroid
    - 4.1.1.2.2. Nintedanib & Corticosteroid
    - 4.1.1.2.3. Pirfenidone & Antitussive
    - 4.1.1.2.4. Others
  - 4.1.1.3. Symptomatic Treatment
4.2. North America Pulmonary Fibrosis Treatment Market Outlook, by Indication, Value (US$ Bn), 2019 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Idiopathic Pulmonary Fibrosis (IPF)
  - 4.2.1.2. Familial PF
  - 4.2.1.3. Others
4.3. North America Pulmonary Fibrosis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. Hospital Pharmacy
  - 4.3.1.2. Retail Pharmacy
  - 4.3.1.3. Mail Order Pharmacy
- 4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America Pulmonary Fibrosis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
- 4.4.1. Key Highlights
  - 4.4.1.1. U.S. Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
  - 4.4.1.2. U.S. Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
  - 4.4.1.3. U.S. Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 4.4.1.4. Canada Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
  - 4.4.1.5. Canada Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
  - 4.4.1.6. Canada Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
- 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Pulmonary Fibrosis Treatment Market Outlook, 2019 - 2031

5.1. Europe Pulmonary Fibrosis Treatment Market Outlook, by Therapy Type, Value (US$ Bn), 2019 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Monotherapy
    - 5.1.1.1.1. Pirfenidone Therapy
    - 5.1.1.1.2. Nintedanib Therapy
    - 5.1.1.1.3. Corticosteroids Therapy
  - 5.1.1.2. Combination Therapy
    - 5.1.1.2.1. Pirfenidone & Corticosteroid
    - 5.1.1.2.2. Nintedanib & Corticosteroid
    - 5.1.1.2.3. Pirfenidone & Antitussive
    - 5.1.1.2.4. Others
  - 5.1.1.3. Symptomatic Treatment
5.2. Europe Pulmonary Fibrosis Treatment Market Outlook, by Indication, Value (US$ Bn), 2019 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Idiopathic Pulmonary Fibrosis (IPF)
  - 5.2.1.2. Familial PF
  - 5.2.1.3. Others
5.3. Europe Pulmonary Fibrosis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Hospital Pharmacy
  - 5.3.1.2. Retail Pharmacy
  - 5.3.1.3. Mail Order Pharmacy
- 5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe Pulmonary Fibrosis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
- 5.4.1. Key Highlights
  - 5.4.1.1. Germany Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
  - 5.4.1.2. Germany Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
  - 5.4.1.3. Germany Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 5.4.1.4. U.K. Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
  - 5.4.1.5. U.K. Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
  - 5.4.1.6. U.K. Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 5.4.1.7. France Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
  - 5.4.1.8. France Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
  - 5.4.1.9. France Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 5.4.1.10. Italy Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
  - 5.4.1.11. Italy Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
  - 5.4.1.12. Italy Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 5.4.1.13. Turkey Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
  - 5.4.1.14. Turkey Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
  - 5.4.1.15. Turkey Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 5.4.1.16. Russia Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
  - 5.4.1.17. Russia Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
  - 5.4.1.18. Russia Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 5.4.1.19. Rest of Europe Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
  - 5.4.1.20. Rest of Europe Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
  - 5.4.1.21. Rest of Europe Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
- 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Cassava Starch Market Outlook, 2019 - 2031

6.1. Asia Pacific Cassava Starch Market Outlook, by Therapy Type, Value (US$ Bn), 2019 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Monotherapy
    - 6.1.1.1.1. Pirfenidone Therapy
    - 6.1.1.1.2. Nintedanib Therapy
    - 6.1.1.1.3. Corticosteroids Therapy
  - 6.1.1.2. Combination Therapy
    - 6.1.1.2.1. Pirfenidone & Corticosteroid
    - 6.1.1.2.2. Nintedanib & Corticosteroid
    - 6.1.1.2.3. Pirfenidone & Antitussive
    - 6.1.1.2.4. Others
  - 6.1.1.3. Symptomatic Treatment
6.2. Asia Pacific Pulmonary Fibrosis Treatment Market Outlook, by Indication, Value (US$ Bn), 2019 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Idiopathic Pulmonary Fibrosis (IPF)
  - 6.2.1.2. Familial PF
  - 6.2.1.3. Others
6.3. Asia Pacific Pulmonary Fibrosis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. Hospital Pharmacy
  - 6.3.1.2. Retail Pharmacy
  - 6.3.1.3. Mail Order Pharmacy
- 6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Pulmonary Fibrosis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
- 6.4.1. Key Highlights
  - 6.4.1.1. China Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
  - 6.4.1.2. China Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
  - 6.4.1.3. China Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 6.4.1.4. Japan Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
  - 6.4.1.5. Japan Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
  - 6.4.1.6. Japan Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 6.4.1.7. South Korea Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
  - 6.4.1.8. South Korea Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
  - 6.4.1.9. South Korea Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 6.4.1.10. India Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
  - 6.4.1.11. India Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
  - 6.4.1.12. India Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 6.4.1.13. Southeast Asia Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
  - 6.4.1.14. Southeast Asia Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
  - 6.4.1.15. Southeast Asia Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 6.4.1.16. Rest of Asia Pacific Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
  - 6.4.1.17. Rest of Asia Pacific Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
  - 6.4.1.18. Rest of Asia Pacific Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
- 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Pulmonary Fibrosis Treatment Market Outlook, 2019 - 2031

7.1. Latin America Pulmonary Fibrosis Treatment Market Outlook, by Therapy Type, Value (US$ Bn), 2019 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Monotherapy
    - 7.1.1.1.1. Pirfenidone Therapy
    - 7.1.1.1.2. Nintedanib Therapy
    - 7.1.1.1.3. Corticosteroids Therapy
  - 7.1.1.2. Combination Therapy
    - 7.1.1.2.1. Pirfenidone & Corticosteroid
    - 7.1.1.2.2. Nintedanib & Corticosteroid
    - 7.1.1.2.3. Pirfenidone & Antitussive
    - 7.1.1.2.4. Others
  - 7.1.1.3. Symptomatic Treatment
7.2. Latin America Pulmonary Fibrosis Treatment Market Outlook, by Indication, Value (US$ Bn), 2019 - 2031
7.3. Latin America Pulmonary Fibrosis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Hospital Pharmacy
  - 7.3.1.2. Retail Pharmacy
  - 7.3.1.3. Mail Order Pharmacy
- 7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Pulmonary Fibrosis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
- 7.4.1. Key Highlights
  - 7.4.1.1. Brazil Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
  - 7.4.1.2. Brazil Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
  - 7.4.1.3. Brazil Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 7.4.1.4. Mexico Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
  - 7.4.1.5. Mexico Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
  - 7.4.1.6. Mexico Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 7.4.1.7. Argentina Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
  - 7.4.1.8. Argentina Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
  - 7.4.1.9. Argentina Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 7.4.1.10. Rest of Latin America Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
  - 7.4.1.11. Rest of Latin America Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
  - 7.4.1.12. Rest of Latin America Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
- 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Pulmonary Fibrosis Treatment Market Outlook, 2019 - 2031

8.1. Middle East & Africa Pulmonary Fibrosis Treatment Market Outlook, by Therapy Type, Value (US$ Bn), 2019 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Monotherapy
    - 8.1.1.1.1. Pirfenidone Therapy
    - 8.1.1.1.2. Nintedanib Therapy
    - 8.1.1.1.3. Corticosteroids Therapy
  - 8.1.1.2. Combination Therapy
    - 8.1.1.2.1. Pirfenidone & Corticosteroid
    - 8.1.1.2.2. Nintedanib & Corticosteroid
    - 8.1.1.2.3. Pirfenidone & Antitussive
    - 8.1.1.2.4. Others
  - 8.1.1.3. Symptomatic Treatment
8.2. Middle East & Africa Pulmonary Fibrosis Treatment Market Outlook, by Indication, Value (US$ Bn), 2019 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Idiopathic Pulmonary Fibrosis (IPF)
  - 8.2.1.2. Familial PF
  - 8.2.1.3. Others
8.3. Middle East & Africa Pulmonary Fibrosis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2031
- 8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Pulmonary Fibrosis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
- 8.4.1. Key Highlights
  - 8.4.1.1. GCC Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
  - 8.4.1.2. GCC Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
  - 8.4.1.3. GCC Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 8.4.1.4. South Africa Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
  - 8.4.1.5. South Africa Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
  - 8.4.1.6. South Africa Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 8.4.1.7. Egypt Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
  - 8.4.1.8. Egypt Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
  - 8.4.1.9. Egypt Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 8.4.1.10. Nigeria Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
  - 8.4.1.11. Nigeria Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
  - 8.4.1.12. Nigeria Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
  - 8.4.1.13. Rest of Middle East & Africa Pulmonary Fibrosis Treatment Market by Therapy Type, Value (US$ Bn), 2019 - 2031
  - 8.4.1.14. Rest of Middle East & Africa Pulmonary Fibrosis Treatment Market by Indication, Value (US$ Bn), 2019 - 2031
  - 8.4.1.15. Rest of Middle East & Africa Pulmonary Fibrosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2031
- 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. By Distribution Channel vs by Indication Heat map
9.2. Manufacturer vs by Indication Heatmap
9.3. Company Market Share Analysis, 2024
9.4. Competitive Dashboard
9.5. Company Profiles
- 9.5.1. F. Hoffman - La Roche Ltd.
  - 9.5.1.1. Company Overview
  - 9.5.1.2. Product Portfolio
  - 9.5.1.3. Financial Overview
  - 9.5.1.4. Business Strategies and Development
- 9.5.2. Boehringer Ingelheim
  - 9.5.2.1. Company Overview
  - 9.5.2.2. Product Portfolio
  - 9.5.2.3. Financial Overview
  - 9.5.2.4. Business Strategies and Development
- 9.5.3. International GmbH
  - 9.5.3.1. Company Overview
  - 9.5.3.2. Product Portfolio
  - 9.5.3.3. Financial Overview
  - 9.5.3.4. Business Strategies and Development
- 9.5.4. Cipla Ltd (Cipla)
  - 9.5.4.1. Company Overview
  - 9.5.4.2. Product Portfolio
  - 9.5.4.3. Financial Overview
  - 9.5.4.4. Business Strategies and Development
- 9.5.5. Gilead Sciences, Inc.
  - 9.5.5.1. Company Overview
  - 9.5.5.2. Product Portfolio
  - 9.5.5.3. Financial Overview
  - 9.5.5.4. Business Strategies and Development
- 9.5.6. Bristol-Myers Squibb Company
  - 9.5.6.1. Company Overview
  - 9.5.6.2. Product Portfolio
  - 9.5.6.3. Financial Overview
  - 9.5.6.4. Business Strategies and Development
- 9.5.7. FibroGen Inc
  - 9.5.7.1. Company Overview
  - 9.5.7.2. Product Portfolio
  - 9.5.7.3. Financial Overview
  - 9.5.7.4. Business Strategies and Development
- 9.5.8. Galecto, Inc
  - 9.5.8.1. Company Overview
  - 9.5.8.2. Product Portfolio
  - 9.5.8.3. Financial Overview
  - 9.5.8.4. Business Strategies and Development
  - 9.5.8.5.

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations